JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors), STAT1 inhibitors(Signal transducer and activator of transcription 1-alpha/beta inhibitors)

Therapeutic Areas

Skin and Musculoskeletal DiseasesOther DiseasesNeoplasms+ [2]

Active Indication

Nonsegmental vitiligoPolycythemia VeraPost-essential thrombocythemia myelofibrosis+ [5]

Inactive Indication

Chronic Myelomonocytic Leukemiaprurigo nodularisPruritus+ [1]

Originator Organization

Apotex, Inc.

Active Organization

Novartis Pharmaceuticals Canada, Inc.

Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.

Beijing Novartis Pharma Co. Ltd.

+ [3]

Inactive Organization

Novartis Pharmaceuticals Corp.Novartis Farmacéutica SA

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Structure/Sequence

Molecular FormulaC17H18N6

InChIKeyHFNKQEVNSGCOJV-OAHLLOKOSA-N

CAS Registry941678-49-5

108

Clinical Trials associated with Ruxolitinib

NCT07498205

/ Not yet recruitingPhase 4IIT

A Randomized Open Label Trial Comparing Momelotinib vs Dose-Adjusted Ruxolitinib For Treatment-Naive, Cytopenic Myelofibrosis

The purpose of this study is to compare momelotinib and ruxolitinib as treatments for myelofibrosis with low blood cell counts. Both drugs are approved by the FDA to treat myelofibrosis. The study asks which drug does a better job at shrinking the spleen.

Start Date08 Aug 2026

Sponsor / Collaborator

SWOG

[+1]

NCT07311746

/ Not yet recruitingPhase 1/2IIT

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

The goal of this clinical research study is to learn if the combination of ruxolitinib with cladribine and venetoclax can help to control the disease in patients with R/R T-PLL.

Start Date01 Jun 2026

Sponsor / Collaborator

The University of Texas MD Anderson Cancer Center

NCT07025538

/ RecruitingPhase 1IIT

Biomarker-Guided Feasibility/Efficacy Trial of Ruxolitinib in Patients With High-Risk of Chronic Graft-Versus-Host Disease Development After Allogeneic Hematopoietic Cell Transplantation

This phase I trial studies how well biomarker-guided ruxolitinib works for the prevention of chronic graft versus host disease (GVHD) in patients that have undergone allogeneic hematopoietic cell transplant (HCT). Allogeneic HCT is the most effective therapy for patients with high-risk blood and bone marrow malignancies. GVHD is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. In chronic GVHD (cGVHD), symptoms occur more than three months after transplantation. Despite significant advances in how allogeneic HCTs are conducted, cGHVD remains a major limitation to the long-term success of the transplant and can impact patients' quality of life post-transplant. Checking GVHD biomarkers in patients' blood after allogeneic HCT may help doctors predict how likely the patient is to develop cGVHD. This information can be used to help guide patients with high levels to receive cGVHD preventative therapy with ruxolitinib. Ruxolitinib works by blocking some of the enzymes that are needed for the development of cGVHD, which may be an effective way to prevent cGVHD in patients with high levels of GVHD biomarkers.

Start Date01 Jun 2026

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Ruxolitinib

100 Translational Medicine associated with Ruxolitinib

100 Patents (Medical) associated with Ruxolitinib

4,158

Literatures (Medical) associated with Ruxolitinib

31 Dec 2026·JOURNAL OF DERMATOLOGICAL TREATMENT

Management of adult vitiligo: approved topical JAK inhibitor and standard therapies

Review

Author: Perrotta, Nicola ; Cantisani, Carmen ; Greco, Maria Elisabetta ; Proietti, Ilaria ; Caro, Alberto di ; Sasso, Francesca Paola ; di Guardo, Antonio ; Potenza, Concetta ; Pellacani, Giovanni ; Fiorito, Luigi Angelo ; Feresin, Francesca ; Nisticò, Steven Paul ; Dattola, Annunziata

INTRODUCTION:

Vitiligo is a chronic autoimmune depigmenting disorder. Ruxolitinib 1.5% cream is currently the only therapy specifically approved for its treatment. In addition, clinical guidelines recommend off label standard therapies, including topical corticosteroids (TCS), topical calcineurin inhibitors (TCI), phototherapy (narrowband UVB or excimer devices), and selected off-label systemic regimens.

MATERIALS AND METHODS:

This review summarizes the scientific evidence on approved and guideline-recommended treatments for adult vitiligo, using a PRISMA-based approach. Only English-language articles published between 2000 and 2025 were included. Interventions comprised approved therapies and standard treatments recommended by guidelines. Outcomes evaluated were changes in Facial and Total Vitiligo Area Scoring Index (F-VASI/T-VASI), quality of life, and safety. Risk of bias was assessed using the Risk of Bias 2 (RoB 2) tool for randomized controlled trials (RCTs) and the Risk of Bias in Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies.

RESULTS:

Ruxolitinib cream demonstrated superior F-VASI responses compared with vehicles in phase II-III RCTs. Evidence supports the efficacy of potent or very potent TCS, TCI, and NB-UVB or targeted 308-nm devices in localized disease.

CONCLUSION:

Systemic regimens show benefits in selected clinical scenarios, although supporting evidence remains heterogeneous. Treatment selection should be individualized based on disease activity, extent, anatomical site, and patient preferences.

31 Dec 2026·ANNALS OF MEDICINE

Efficacy and safety of Ruxolitinib-based combination therapy in the patients with Myelofibrosis (MF): a systematic review and meta-analysis

Review

Author: Li, Yuxin ; Sun, Wanling ; Cao, Yaofang ; Hui, Wuhan ; Tan, Shuai

BACKGROUND:

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm. Although Ruxolitinib, a JAK1/2 inhibitor, remains the cornerstone of MF treatment, it does not reverse disease progression, and resistance frequently emerges. These limitations have prompted investigation into combination therapies targeting pathways beyond the JAK-STAT axis. This meta-analysis aims to evaluate the efficacy and safety of Ruxolitinib-based combination therapies in patients with MF.

METHODS:

We conducted a systematic search of databases for studies published through August 1, 2025. Thirteen distinct Ruxolitinib-based combination regimens were included. Primary efficacy endpoints were ≥35% spleen volume reduction at 24 weeks (SVR35) and ≥50% reduction in total symptom score (TSS50). Safety endpoints focused on the incidence of grade 3/4 thrombocytopenia and anemia. Subgroup analyses were performed based on prior JAK inhibitor exposure and therapeutic mechanism of action.

RESULTS:

A total of 19 studies comprising 1,088 patients were included in the meta-analysis. Among JAK inhibitor-naïve patients, the combination of Ruxolitinib with Selinexor demonstrated the highest efficacy (SVR35: 92%; TSS50: 78%), followed by Ruxolitinib plus BMS-986158 (SVR35: 90%). For patients with prior JAK inhibitor exposure, Ruxolitinib plus Siremadlin (SVR35: 45%) showed notable activity.

CONCLUSION:

For JAK inhibitor-naïve patients, Ruxolitinib-based combination regimens demonstrated satisfactory clinical responses and the potential for meaningful disease control. For patients with prior JAK inhibitor exposure, the addition of combination therapy drugs may further enhance the efficacy. Personalized treatment selection remains essential, as therapeutic efficacy is significantly influenced by prior JAK inhibitor exposure.

01 Jun 2026·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Raman-guided analysis of drug response combined with chemometrics helps monitor the effect of ruxolitinib on acute lymphoblastic leukemia

Article

Author: Nowakowska, Anna M ; Adamczyk, Adriana ; Baranska, Małgorzata ; Ostrowska, Kinga ; Jakubowska, Justyna ; Majzner, Katarzyna ; Stawoski, Kacper ; Młynarski, Wojciech ; Szewczyk, Marta ; Pastorczak, Agata

Ruxolitinib (RUX), a selective JAK1/JAK2 inhibitor, is considered a therapeutic option for childhood B-cell precursor acute lymphoblastic leukemia (B-ALL) with JAK2 gain-of-function mutations. This study aimed to evaluate whether Raman spectroscopy combined with chemometric analysis can monitor the biochemical effects of RUX treatment in B-ALL cell lines. We employed single-cell confocal Raman imaging, flow cytometry, and Western blotting to assess the response of JAK2-mutated (MUTZ-5 and MHH-CALL-4) and wild-type (SEM) B-ALL cells to 10 μM RUX treatment over 48 h. Dimensionality reduction methods (PCA, t-SNE) and classification approach (o-PLS-DA) were applied to the spectral data to identify treatment-induced changes. RUX selectively reduced STAT5 phosphorylation and induced distinct Raman spectral shifts in JAK2-mutant cells, particularly in DNA- and protein-related bands. No significant changes were observed in JAK2 wild-type cells. The results demonstrate that Raman spectroscopy, when integrated with multivariate analysis, enables the non-destructive tracking of leukemia cell responses to targeted therapy and may support the development of phenotyping tools for drug monitoring in precision oncology.

News (Medical) associated with Ruxolitinib

04 May 2026

·www.biospace.com

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

Jakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi ® (ruxolitinib) Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi Jakafi XR will be available for pharmacy orders by May 8 WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury, Chief Executive Officer, Incyte. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-established role of Jakafi in clinical practice.” FDA approval was based on a clinical study which demonstrated that a single 55 mg Jakafi XR tablet taken once-daily (QD) is bioequivalent to a single 25 mg Jakafi tablet, the immediate-release (IR) dosage form, taken twice-daily (BID). This means that, based on key measures of steady-state drug exposure, it delivers the same active ingredient at comparable levels throughout the day, indicating the potential for similar clinical benefit. 1 The safety of Jakafi XR has been established from adequate and well-controlled studies of Jakafi in adult patients with myelofibrosis, polycythemia vera, and adult and pediatric patients with acute and chronic graft-versus-host-disease. The most common adverse reactions associated with Jakafi in these studies include: For certain patients with MF and PV: low platelet or red blood cell counts, bruising, dizziness, headache and diarrhea; For patients with acute GVHD: low platelet counts, low red or white blood cell counts, infections and swelling; And for patients with chronic GVHD: low red blood cell or platelet counts and infections, including viral infections. 2 “Patients living with chronic conditions like MPNs and GVHD often struggle with managing complex treatment regimens or have multiple conditions,” said Naveen Pemmaraju, M.D., Professor of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center. “Since its initial approval in 2011, ruxolitinib has helped transform the treatment landscape for patients with MPNs and GVHD. With the approval of Jakafi XR, appropriate patients now have the choice of a single daily tablet.” Researchers at UT MD Anderson have led several clinical trials in the development of ruxolitinib. Incyte is committed to supporting patients and removing barriers to access medicines. Eligible patients in the U.S. who are prescribed Jakafi XR have access to IncyteCARES (Connecting to Access, Reimbursement, Education and Support), a comprehensive program offering personalized patient support, including financial assistance and ongoing education and additional resources. More information about IncyteCARES is available by visiting or calling 1-855-452-5234, Monday through Friday, from 8 a.m. to 8 p.m. ET. About Myelofibrosis Myelofibrosis (MF) is a part of a group of rare, chronic blood cancers called myeloproliferative neoplasms, or MPNs. MF occurs when a bone marrow defect results in an abnormal production of blood cells, causing scar tissue to form, which can lead to severe anemia, weakness, fatigue and an enlarged spleen and liver. MF can result from a progression of other bone marrow diseases, including polycythemia vera and essential thrombocythemia, or it can occur on its own. 3 About Polycythemia Vera Polycythemia Vera (PV) is a part of a group of rare, chronic blood cancers called myeloproliferative neoplasms, or MPNs. 3 PV occurs when bone marrow produces too many red blood cells, white blood cells and often platelets. Increased red blood cells and platelets can cause the blood to thicken, leading to an increased risk of blood clotting complications, including deep vein thrombosis, stroke or heart attack. 4 About Graft-Versus-Host Disease Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) in which the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) tract and liver. 5 About Jakafi XR™ (ruxolitinib) Extended-Release Tablets Jakafi XR™ (ruxolitinib) extended-release tablets are a once-daily (QD) formulation of ruxolitinib, a first-in-class JAK1/JAK2 inhibitor, approved by the U.S. FDA for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults; polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older; and chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. It is not known if Jakafi XR is safe or effective in children for treatment of myelofibrosis or polycythemia vera. Jakafi XR and the Jakafi XR logo are trademarks of Incyte. About Jakafi ® (ruxolitinib) Jakafi ® (ruxolitinib) is a JAK1/JAK2 inhibitor approved by the U.S. FDA for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute GVHD in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. It is not known if Jakafi is safe or effective in children for treatment of myelofibrosis or polycythemia vera. Jakafi is marketed by Incyte in the U.S. and by Novartis as Jakavi ® (ruxolitinib) outside the U.S. Jakafi and the Jakafi logo are registered trademarks of Incyte. Jakavi is a registered trademark of Novartis AG in countries outside the United States. IMPORTANT SAFETY INFORMATION JAKAFI or JAKAFI XR can cause serious side effects, including: Low blood counts: JAKAFI or JAKAFI XR may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking JAKAFI or JAKAFI XR and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start and regularly during your treatment. Your healthcare provider may change your dose or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as: unusual bleeding bruising tiredness shortness of breath a fever Infection: You may be at risk for developing a serious infection during treatment with JAKAFI or JAKAFI XR. Tell your healthcare provider if you develop any of the following symptoms of infection: chills nausea vomiting aches weakness fever painful skin rash or blisters Worsening of symptoms after interrupting or stopping treatment. Signs and symptoms of myelofibrosis may worsen after you stop treatment. Do not interrupt or stop treatment without talking to your healthcare provider. Tell your healthcare provider right away if you have any of the following after stopping treatment: fever trouble breathing weakness night sweats feeling dizzy or lightheaded pain in left upper stomach area or left shoulder Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will regularly check your skin during your treatment. Tell your healthcare provider if you develop any new or changing skin lesions during treatment. Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking JAKAFI or JAKAFI XR and as needed. Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you get any symptoms of a heart attack or stroke during treatment with JAKAFI or JAKAFI XR, including: discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded weakness in one part or on one side of your body slurred speech Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with JAKAFI or JAKAFI XR, including: swelling, pain, or tenderness in one or both legs sudden, unexplained chest or upper back pain shortness of breath or difficulty breathing Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers. The most common side effects of JAKAFI or JAKAFI XR include: for certain types of polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea for certain types of myelofibrosis (MF) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling for chronic GVHD – low red blood cell or platelet counts and infections, including viral infections These are not all the possible side effects. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects. Before taking JAKAFI or JAKAFI XR, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking your medical conditions, including if you have or had low white or red blood cell counts have an infection have or had tuberculosis (TB) or have been in close contact with someone who has TB had shingles (herpes zoster) have or had hepatitis B have a high level of fat in your blood (high blood cholesterol or triglycerides) have or have had a blood clot, heart attack, other heart problems, or stroke are a current or past smoker had cancer have or had liver or kidney problems or are on dialysis. If you are on dialysis, JAKAFI or JAKAFI XR should be taken after your dialysis have any other medical condition Women should not take JAKAFI or JAKAFI XR while pregnant or planning to become pregnant. Do not breastfeed during treatment with JAKAFI or JAKAFI XR and for 2 weeks after the final dose. How should I take JAKAFI or JAKAFI XR? Take exactly as your healthcare provider tells you. Do not change your dose or stop taking JAKAFI or JAKAFI XR without first talking to your healthcare provider. If you stop treatment, symptoms of your condition may return. If you miss a dose, take your next dose at your regular time. Do NOT take 2 doses at the same time. You may have regular blood tests during your treatment. Based on the results, your healthcare provider may change your dose or stop JAKAFI or JAKAFI XR. IF YOU ARE PRESCRIBED JAKAFI: Take JAKAFI 2 times a day or exactly as your healthcare provider tells you, with or without food. JAKAFI may also be given through certain nasogastric tubes. Tell your healthcare provider if you cannot take JAKAFI by mouth. Your healthcare provider will decide if you can take JAKAFI through a nasogastric tube. Ask your healthcare provider to give you specific instructions on how to properly take JAKAFI through a nasogastric tube. IF YOU ARE PRESCRIBED JAKAFI XR: Take JAKAFI XR 1 time a day with or without food. Swallow JAKAFI XR whole. Do not split, crush, or chew. Please see the Full Prescribing Information, including Patient Information , which includes a more complete discussion of the risks associated with JAKAFI or JAKAFI XR at Jakafi.com . You are encouraged to report negative side effects of prescription drugs to the FDA. Visit , or call 1-800-FDA-1088 . You may also report side effects to Incyte Medical Information at 1-855-463-3463. About Incyte ® Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity. To learn more, visit Incyte.com and Investor.Incyte.com . Follow us on social media: LinkedIn , X and Instagram . Incyte is a registered trademark of Incyte. Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this release, including statements regarding when Jakafi XR will be available in pharmacies; Incyte’s leadership in hematology and its commitment to supporting the MPN and GVHD communities, Incyte’s focus on advancing innovative treatments that help address the needs of patients, the potential for Jakafi XR to provide a successful treatment option for patients and offer patients and their providers choice and flexibility and Incyte’s intent to work closely with payers and providers to help ensure access to Jakafi XR, contain predictions, estimates, and other forward-looking statements. These forward-looking statements are based on Incyte’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties regarding research and development of products and product candidates, determinations made by the FDA, EMA and other regulatory agencies, Incyte’s dependence on its relationships with and changes in the plans of its collaboration partners; the efficacy or safety of Incyte’s products, the acceptance of Incyte’s products in the marketplace; market competition, unexpected variations in the demand for Incyte’s products; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for Incyte’s products, sales, marketing, manufacturing and distribution requirements, including Incyte’s ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional products that become approved; greater than expected expenses, including expenses relating to litigation or strategic activities, variations in foreign currency exchange rates; and other risks detailed in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements _________________________ 1 Gong X, et al. ASH 2025. Poster 5045. 2 Data on File. Incyte Corporation. 3 Blood Cancer United. Myelofibrosis (MF). . Accessed May 2026. 4 Blood Cancer United. Polycythemia vera (PV) . Accessed May 2026. 5 National Library of Medicine. The European Blood and Marrow Transplantation Textbook for Nurses: Under the Auspices of EBMT. . Accessed May 2026. Contacts Media media@incyte.com Investors ir@incyte.com

Drug Approval

03 May 2026

·www.prnewswire.com

New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]

NIKTIMVO® (axatilimab) approved by the Therapeutic Goods Administration (TGA) under Priority Review for the treatment of eligible Australian patients with chronic graft-versus-host disease[2] Australia becomes the first country to obtain Marketing Authorisation for NIKTIMVO since approval by the US FDA[3] Australian-led research played key role in the development of NIKTIMVO, a first-in-class novel colony stimulating factor-1 receptor (CSF-1R) blocking antibody.[1],[4] SINGAPORE, May 3, 2026 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in Australia by the Therapeutic Goods Administration (TGA) for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and paediatric patients 6 years and older weighing at least 40 kg. NIKTIMVO was assessed through the TGA's Priority Review pathway and is the first approved anti-colony stimulating factor-1 receptor (anti-CSF-1R) antibody for cGVHD.[1],[2],[5] Through its novel mechanism of action, NIKTIMVO specifically targets the key drivers of inflammation and fibrosis in tissues throughout the body, helping to address the serious and potentially life-threatening complications associated with cGVHD.[6],[7] "Chronic GVHD is a significant long-term concern in patients with blood cancer requiring stem cell or bone marrow transplantation, and is characterised by multi-organ inflammation and fibrosis, leading to increased morbidity and non-relapse mortality," said Professor Jeff Szer, Clinical Haematologist at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital. "The Australian approval of NIKTIMVO is welcome news and will provide an important new treatment option for patients with chronic GVHD who continue to progress on other therapies, experience a higher symptom burden, and a decline in function and quality of life," said Professor Szer. "I urge the Government and Specialised Therapeutics to determine an appropriate pathway to reimbursement to ensure eligible patients can have equitable access to this therapy as soon as possible." Graft-versus-host disease (GVHD) occurs when donated stem cells (the graft) mature into immune cells and attack the healthy cells in the patient's body (the host).[8] Approximately 600 allogeneic stem cell transplants — where a patient receives stem cells from a donor to replace their diseased blood cells and repair their bone marrow — are carried out in Australia each year.[8],[9] Chronic GVHD can occur at any time but typically develops 4-6 months after the transplant and affects approximately 40-50% of transplant recipients.[7],[8],[10] In the majority of cases, three or more organs are involved, ranging from mild skin rashes, to muscle weakness, pain and joint stiffness, which can impair overall functional capacity, to potentially life-threatening muti-organ failure.[8],[11] In June 2025, Specialised Therapeutics (ST) entered into an exclusive partnering agreement with Incyte (NASDAQ:INCY) to commercialise NIKTIMVO in Australia, New Zealand and Singapore. "Chronic GVHD remains an area of significant unmet need for Australians with blood cancer who have received donor stem cell or bone marrow transplants," said Carlo Montagner, ST Chief Executive Officer. "For patients who develop chronic GVHD, almost 50% will require at least three different therapies[7],[10],[11], reinforcing the need for additional effective treatment options." The development of NIKTIMVO was made possible due to important pre-clinical Australian research, which commenced in 2014.[4] Scientists from QIMR Berghofer made the world-first discovery, identifying both the cellular process that causes cGVHD, and the antibody that could block this process and prevent the disease's development.[4] "We are extremely proud to have secured local approval for NIKTIMVO, which would not have been possible without the pioneering work led by these Australian scientists over a decade ago," said Mr Montagner. "Chronic GVHD may lead to debilitating symptoms that can be extremely difficult to treat.[9] As the first country to obtain Marketing Authorisation for NIKTIMVO since it was approved by the US FDA in August 2024[3], we are pleased that it will soon be available for Australian prescribers and patients in need of new therapeutic options." ST is currently exploring the reimbursement of NIKTIMVO through the Pharmaceutical Benefits Scheme (PBS) for eligible adults and patients 6 years and older with cGVHD. The TGA approval of NIKTIMVO was based on data from the pivotal phase 2 global AGAVE-201 clinical trial, which evaluated its safety and efficacy in 241 adult and some paediatric patients with refractory cGVHD who received at least two prior lines of systemic therapy.[12] AGAVE-201 involved 121 clinical trial sites across 16 countries, including patients from Australia, Singapore, South Korea and Taiwan.[12] The overall response rate (ORR) among patients in the study who received NIKTIMVO was 74% (95% CI 63, 83) at the approved dose (0.3 mg/kg every 2 weeks).[13],[14] Additionally, 60% of patients maintained a response at 12 months.[13],[14] In clinical studies, treatment with NIKTIMVO was generally well-tolerated, with a safety profile that was manageable and consistent with the mechanism of action of CSF-1R inhibition.[6],[13],[14] The most common adverse events were dose-dependent transient laboratory abnormalities related to CSF-1R blockade.[6],[13],[14] For further details on NIKTIMVO, contact your healthcare professional and please refer to the approved Australian Consumer Medicine Information or Product Information available from ST Medical Information on 1300 798 820. PBS Information: NIKTIMVO is not listed on the Pharmaceutical Benefits Scheme (PBS). Important safety Information on NIKTIMVO[ 14] WARNINGS AND PRECAUTIONS: Infusion-Related Reactions – NIKTIMVO can cause infusion-related reactions. Infusion-related reactions, including hypersensitivity reactions, occurred in 18% of patients who received NIKTIMVO in the clinical trial (AGAVE-201), with Grade 3 or 4 reactions in 1.3%. ADVERSE REACTIONS: The safety of axatilimab was evaluated in 79 patients with cGVHD enrolled in the AGAVE-201 study. No fatal or serious adverse reactions occurred in patients receiving axatilimab. No patients permanently discontinued axatilimab due to an adverse reaction. Dose interruptions due to an adverse reaction occurred in 3.8% of patients. The adverse reactions leading to dose interruption were elevated liver enzymes, amylase increased, fatigue, and lipase increased (1.3% each). The most common (≥ 15%) adverse reactions were fatigue, elevated liver enzymes, and infusion related reactions. Immunogenicity: Antidrug antibodies (ADAs) were assessed in 276 patients with cGVHD who received axatilimab. The incidence of axatilimab treatment-emergent ADAs was 33.7% (93/276) using a bridging enzyme-linked immunosorbent assay following a median exposure time of 7.8 months. Neutralising antibodies were detected in 47 of 93 cGVHD patients with treatment-emergent ADAs. There was no clinically significant effect of anti-axatilimab antibodies or neutralising antibodies on the pharmacokinetics, pharmacodynamics, safety, or effectiveness of axatilimab with the 0.3 mg/kg every 2 weeks dosage regimen. USE IN SPECIFIC POPULATIONS: Lactation – Because of the potential for serious adverse reactions in a breastfed child, women should not breastfeed during treatment and for 30 days after the last dose of NIKTIMVO. Females and Males of Reproductive Potential – Pregnancy Testing, verify pregnancy status in females of reproductive potential prior to initiating NIKTIMVO; Contraception, females of reproductive potential should use effective contraception during treatment with NIKTIMVO and for 30 days after the last dose of NIKTIMVO. Embryo-Foetal Toxicity – based on its mechanism of action, NIKTIMVO may cause foetal harm when administered to a pregnant woman. About NIKTIMVO ® (axatilimab)[ 14] NIKTIMVO is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the US in August 2024 for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and paediatric patients weighing at least 40 kg (88.2 lbs).[1],[3] In Australia, NIKTIMVO is indicated for the treatment of chronic graft-versus host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and paediatric patients 6 years and older weighing at least 40 kg.[14] ▼ This medicine is included in the TGA Black Triangle Scheme. Please report suspected adverse events to the TGA. In 2016, Syndax licensed exclusive worldwide rights to develop and commercialise NIKTIMVO from UCB. In September 2021, Syndax and Incyte entered into an exclusive worldwide co-development and co-commercialisation license agreement for NIKTIMVO in chronic GVHD and any future indications. NIKTIMVO is being studied in frontline combination trials in chronic GVHD – a Phase 2 combination trial with ruxolitinib (NCT06388564) and a Phase 3 combination trial with steroids (NCT06585774) are underway. NIKTIMVO is also being studied in an ongoing Phase 2 trial in patients with idiopathic pulmonary fibrosis (NCT06132256). NIKTIMVO is a trademark of Incyte. All other trademarks are the property of their respective owners. About the AGAVE-201 Study[ 13],[14] AGAVE-201 was a global Phase 2, open-label, randomised, multicentre dose-ranging trial that evaluated the efficacy, safety and tolerability of axatilimab in 241 adult and paediatric patients with recurrent or refractory active chronic GVHD whose disease had progressed after two prior therapies. Patients were randomised to one of three treatment groups that investigated a distinct dose of axatilimab administered at 0.3 mg/kg every two weeks, 1.0 mg/kg every two weeks or 3.0 mg/kg every four weeks. The trial's primary endpoint was the proportion of patients in each dose group who achieved an objective response as defined by 2014 NIH Consensus Criteria for chronic GVHD by cycle 7 day 1. Secondary endpoints include duration of response, percent reduction in daily steroids dose, organ specific response rates and validated quality-of-life assessments using the modified Lee Symptom Scale. Adverse events leading to discontinuation of axatilimab occurred in 6% of the patients in the 0.3-mg dose group, 22% in the 1-mg dose group, and 18% in the 3-mg dose group. Visit for further information. About Specialised Therapeutics Founded in 2007, Specialised Therapeutics is an independent specialty pharmaceutical company, providing new therapies and technologies to patients in Australia, New Zealand and across Southeast Asia. Headquartered in Singapore, ST partners with global pharmaceutical, biotech and diagnostic companies to bring novel healthcare opportunities to patients who are impacted by a range of diseases. ST has built a strong track record of success, navigating complex regulatory, reimbursement and commercialisation environments in its diverse regions. The ST mission is to provide specialty therapies where there is an unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. Additional information can be found at . SOURCE Specialised Therapeutics 21% more press release views with Request a Demo

Phase 3Phase 2Clinical ResultDrug ApprovalLicense out/in

01 May 2026

·investor.incyte.com

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease

WILMINGTON, Del. --(BUSINESS WIRE)--May 1, 2026-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury , Chief Executive Officer, Incyte . “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-established role of Jakafi in clinical practice.” FDA approval was based on a clinical study which demonstrated that a single 55 mg Jakafi XR tablet taken once-daily (QD) is bioequivalent to a single 25 mg Jakafi tablet, the immediate-release (IR) dosage form, taken twice-daily (BID). This means that, based on key measures of steady-state drug exposure, it delivers the same active ingredient at comparable levels throughout the day, indicating the potential for similar clinical benefit.1 The safety of Jakafi XR has been established from adequate and well-controlled studies of Jakafi in adult patients with myelofibrosis, polycythemia vera, and adult and pediatric patients with acute and chronic graft-versus-host-disease. The most common adverse reactions associated with Jakafi in these studies include: “Patients living with chronic conditions like MPNs and GVHD often struggle with managing complex treatment regimens or have multiple conditions,” said Naveen Pemmaraju , M.D., Professor of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center . “Since its initial approval in 2011, ruxolitinib has helped transform the treatment landscape for patients with MPNs and GVHD. With the approval of Jakafi XR, appropriate patients now have the choice of a single daily tablet.” Researchers at UT MD Anderson have led several clinical trials in the development of ruxolitinib. Incyte is committed to supporting patients and removing barriers to access medicines. Eligible patients in the U.S. who are prescribed Jakafi XR have access to IncyteCARES (Connecting to Access, Reimbursement, Education and Support), a comprehensive program offering personalized patient support, including financial assistance and ongoing education and additional resources. More information about IncyteCARES is available by visiting www.incytecares.com or calling 1-855-452-5234, Monday through Friday, from 8 a.m. to 8 p.m. ET . About Myelofibrosis Myelofibrosis (MF) is a part of a group of rare, chronic blood cancers called myeloproliferative neoplasms, or MPNs. MF occurs when a bone marrow defect results in an abnormal production of blood cells, causing scar tissue to form, which can lead to severe anemia, weakness, fatigue and an enlarged spleen and liver. MF can result from a progression of other bone marrow diseases, including polycythemia vera and essential thrombocythemia, or it can occur on its own.3 About Polycythemia Vera Polycythemia Vera (PV) is a part of a group of rare, chronic blood cancers called myeloproliferative neoplasms, or MPNs.3 PV occurs when bone marrow produces too many red blood cells, white blood cells and often platelets. Increased red blood cells and platelets can cause the blood to thicken, leading to an increased risk of blood clotting complications, including deep vein thrombosis, stroke or heart attack.4 About Graft-Versus-Host Disease Graft-versus-host disease (GVHD) is a condition that can occur after an allogeneic stem cell transplant (the transfer of stem cells from a donor) in which the donated cells initiate an immune response and attack the transplant recipient’s organs, leading to significant morbidity and mortality. There are two major forms of GVHD: acute, which generally occurs within 100 days of transplant, and chronic, which generally occurs after 100 days of transplant. Both forms can affect multiple organ systems, including the skin, gastrointestinal (digestive) tract and liver.5 About Jakafi XR™ (ruxolitinib) Extended-Release Tablets Jakafi XR™ (ruxolitinib) extended-release tablets are a once-daily (QD) formulation of ruxolitinib, a first-in-class JAK1/JAK2 inhibitor, approved by the U.S. FDA for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis in adults; polycythemia vera in adults who have had an inadequate response to or are intolerant of hydroxyurea; steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older; and chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. It is not known if Jakafi XR is safe or effective in children for treatment of myelofibrosis or polycythemia vera. Jakafi XR and the Jakafi XR logo are trademarks of Incyte . About Jakafi® (ruxolitinib) Jakafi® (ruxolitinib) is a JAK1/JAK2 inhibitor approved by the U.S. FDA for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute GVHD in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. It is not known if Jakafi is safe or effective in children for treatment of myelofibrosis or polycythemia vera. Jakafi is marketed by Incyte in the U.S. and by Novartis as Jakavi® (ruxolitinib) outside the U.S. Jakafi and the Jakafi logo are registered trademarks of Incyte . Jakavi is a registered trademark of Novartis AG in countries outside the United States . IMPORTANT SAFETY INFORMATION JAKAFI or JAKAFI XR can cause serious side effects, including: Low blood counts: JAKAFI or JAKAFI XR may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking JAKAFI or JAKAFI XR and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start and regularly during your treatment. Your healthcare provider may change your dose or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as: Infection: You may be at risk for developing a serious infection during treatment with JAKAFI or JAKAFI XR. Tell your healthcare provider if you develop any of the following symptoms of infection: Worsening of symptoms after interrupting or stopping treatment. Signs and symptoms of myelofibrosis may worsen after you stop treatment. Do not interrupt or stop treatment without talking to your healthcare provider. Tell your healthcare provider right away if you have any of the following after stopping treatment: Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will regularly check your skin during your treatment. Tell your healthcare provider if you develop any new or changing skin lesions during treatment. Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with JAKAFI or JAKAFI XR. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking JAKAFI or JAKAFI XR and as needed. Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you get any symptoms of a heart attack or stroke during treatment with JAKAFI or JAKAFI XR, including: Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with JAKAFI or JAKAFI XR, including: Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers. The most common side effects of JAKAFI or JAKAFI XR include: These are not all the possible side effects. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects. Before taking JAKAFI or JAKAFI XR, tell your healthcare provider about: Women should not take JAKAFI or JAKAFI XR while pregnant or planning to become pregnant. Do not breastfeed during treatment with JAKAFI or JAKAFI XR and for 2 weeks after the final dose. How should I take JAKAFI or JAKAFI XR? Please see the Full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with JAKAFI or JAKAFI XR at Jakafi.com. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Incyte Medical Information at 1-855-463-3463. About Incyte ® Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity. To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram. Incyte is a registered trademark of Incyte . Forward-Looking Statements Except for the historical information set forth herein, the matters set forth in this release, including statements regarding when Jakafi XR will be available in pharmacies; Incyte’s leadership in hematology and its commitment to supporting the MPN and GVHD communities, Incyte’s focus on advancing innovative treatments that help address the needs of patients, the potential for Jakafi XR to provide a successful treatment option for patients and offer patients and their providers choice and flexibility and Incyte’s intent to work closely with payers and providers to help ensure access to Jakafi XR, contain predictions, estimates, and other forward-looking statements. These forward-looking statements are based on Incyte’s current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties regarding research and development of products and product candidates, determinations made by the FDA, EMA and other regulatory agencies, Incyte’s dependence on its relationships with and changes in the plans of its collaboration partners; the efficacy or safety of Incyte’s products, the acceptance of Incyte’s products in the marketplace; market competition, unexpected variations in the demand for Incyte’s products; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for Incyte’s products, sales, marketing, manufacturing and distribution requirements, including Incyte’s ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional products that become approved; greater than expected expenses, including expenses relating to litigation or strategic activities, variations in foreign currency exchange rates; and other risks detailed in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report on Form 10-K and its quarterly report on Form 10-Q for the quarter ended March 31, 2026 . Incyte disclaims any intent or obligation to update these forward-looking statements View source version on businesswire.com: https://www.businesswire.com/news/home/20260501334677/en/ Media media@incyte.com Investors ir@incyte.com Source: Incyte

Drug Approval

100 Deals associated with Ruxolitinib

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
prurigo nodularis	Phase 3	China	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	15 Dec 2025
Pruritus	Phase 3	China	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	15 Dec 2025
Nonsegmental vitiligo	Phase 3	China	Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.	01 Nov 2024
Chronic Myelomonocytic Leukemia	Phase 2	Spain	Novartis Farmacéutica SA	21 Mar 2014
Polycythemia Vera	Phase 2	Australia	Novartis Pharmaceuticals Corp.	08 May 2013
Polycythemia Vera	Phase 2	Belgium	Novartis Pharmaceuticals Corp.	08 May 2013
Polycythemia Vera	Phase 2	Canada	Novartis Pharmaceuticals Corp.	08 May 2013
Polycythemia Vera	Phase 2	Denmark	Novartis Pharmaceuticals Corp.	08 May 2013
Polycythemia Vera	Phase 2	France	Novartis Pharmaceuticals Corp.	08 May 2013
Polycythemia Vera	Phase 2	Germany	Novartis Pharmaceuticals Corp.	08 May 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


AAD2026	Not Applicable	-	5	ruxolitinib 1.5% cream	nfuedakvbm(jzowanrzay) = sinusitis exacerbation (n=1) atiiipybfc (khoknjmqpr )	Positive	27 Mar 2026
AAD2026	Not Applicable	Vitiligo	13,224	Topical corticosteroids (TCS)	wivczarcmn(ytulybzhzp) = emfocmhdaz srlhvdlsqa (uzvjnubrmg )	Negative	27 Mar 2026
				Topical calcineurin inhibitors (TCI)	whotpkbnrg(cbkcmjmwap) = amxhbggfdb heljliftvh (jqwvjlrioy ) View more
AAD2026	Not Applicable	Alopecia Universalis	329	Tofacitinib	cafgvueckm(lxjkvhxbfa) = Tofacitinib was associated with shingles, acneiform eruptions, infections, gastrointestinal symptoms, weight gain, and one case of multiple sclerosis. Ruxolitinib caused mild cytopenias and gastrointestinal issues; upadacitinib led to hair depigmentation; filgotinib caused acneiform eruptions. Safety data for ritlecitinib, abrocitinib, and deuruxolitinib were limited. ilvqruphgp (dmcsznqhjc )	Positive	27 Mar 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Chronic graft-versus-host disease	7	Ruxolitinib (chronic graft versus host disease)	ykklelnpdt(krqkobpdly) = Five patients had been able to discontinue ruxolitinib due to disease control. ldtfffsjyg (cuwgqcrjys )	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Chronic graft-versus-host disease	86	Ruxolitinib Taper or Discontinuation	dtayiwxpjb(hvyjpbdwpa) = khgtkouvac iejcwsppoy (srmlmuwtlc ) View more	Positive	04 Feb 2026
				Ruxolitinib Taper or Discontinuation	dtayiwxpjb(hvyjpbdwpa) = ucwjelfbaq iejcwsppoy (srmlmuwtlc ) View more
NCT05998395 (CTgov)	Phase 1/2	Malignant Atrophic Papulosis	1	Ruxolitinib	wpipzodven = zqhppqtuuv mimauqklgi (bmjbznulnb, qctmiitqlx - zxkwsvhruy) View more	-	03 Feb 2026
NCT03654768 (CTgov)	Phase 2	Chronic phase chronic myeloid leukemia	81	dasatinib+nilotinib+imatinib+bosutinib (Single Agent TKI)	lqbyfswigp = rgvuecyyyv uirqbbzxjk (ymzdiadzqm, xbsljimcub - nvvquoqrne) View more	-	18 Dec 2025
				Ruxolitinib (TKI + Ruxolitinib)	lqbyfswigp = klyuslilbt uirqbbzxjk (ymzdiadzqm, uxizukdgyu - raceknfqlo) View more
ASH2025	Not Applicable	Polycythemia Vera	10,508	Ruxolitinib	slnnvczhca(rshvxdfzli) = mihdtxrxmf kobxywwosb (bvafkcnlns )	Negative	06 Dec 2025
				Hydroxyurea	slnnvczhca(rshvxdfzli) = jiwwbgabml kobxywwosb (bvafkcnlns )
ASH2025	Not Applicable	Steroid Refractory Graft Versus Host Disease	2,533	Remestemcel-L	mfyzontgvt(kejxmuklfv) = gvlejliwzk lgpgkwyzte (uhocwwbmvw, 0.33 - 1.26) View more	Positive	06 Dec 2025
				Ruxolitinib	mfyzontgvt(kejxmuklfv) = xbezbxpmzf lgpgkwyzte (uhocwwbmvw, 0.69 - 1.43) View more
ChiCTR2300072086 (APL2022, ASH2025)	Phase 1	Acute Promyelocytic Leukemia	98	Ruxolitinib 5mg bid + dexamethasone 10mg per day	mibtiibdoz(eqcykkgmdp) = pbjeyqbdlq hmfzhuvkot (pvlgnfypyx ) View more	Positive	06 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis